Blog
RSS FeedPosted by Michael Wonder on 21 Apr 2022
Ontario family forced to fight for life-saving drug highlights need for national rare disease strategy
21 April 2022 - Beth Vanstone doesn’t want anyone else to have to fight for access to life saving medications. ...
Posted by Michael Wonder on 13 Apr 2022
Paxlovid ‘inaccessible’ to many patients in Canada. Here’s why that needs to change.
13 April 2022 - A pill to treat COVID-19 appears to be the country’s best hope, outside of vaccines and ...
Posted by Michael Wonder on 07 Apr 2022
CADTH launches consultations on proposals to enhance drug review processes
4 April 2022 - CADTH has launched consultations on a proposed process for non-sponsored reimbursement reviews and a streamlined process ...
Posted by Michael Wonder on 05 Apr 2022
CADTH Strategy 2022-2025: anticipate, innovate and transform
5 April 2022 - CADTH is pleased to share Ahead of the Curve: Shaping Future-Ready Heath Systems, the agency's new ...
Posted by Michael Wonder on 22 Mar 2022
Valeo Pharma secures additional public reimbursement for Redesca, Enerzair Breezhaler and Atectura Breezhaler
22 March 2022 - Canadian provincial public reimbursement now complete for Redesca with the addition of British Columbia. ...
Posted by Michael Wonder on 02 Mar 2022
Teva Canada welcomes public drug plan reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the non-insured health benefits program for patients prescribed Ajovy (fremanezumab) for the preventive treatment of migraine in adults
2 March 2022 - Public formulary and program coverage makes AJOVY® accessible to more migraine patients across Canada. ...
Posted by Michael Wonder on 02 Mar 2022
ALS Canada marks Rare Disease Day 2022 by calling on Ontario to champion expedited access to ALS therapies
28 February 2022 - The ALS Society of Canada Cana today marks Rare Disease Day 2022 by calling on the ...
Posted by Michael Wonder on 24 Feb 2022
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Ontario, Manitoba and New Brunswick
24 February 2022 - Private insurance coverage across Canada exceeds 90%. ...
Posted by Michael Wonder on 22 Feb 2022
New PMPRB report shows significant consistency in public drug plan coverage across Canada for drugs subject to "Common Drug Review" process
22 February 2022 - The Patented Medicine Prices Review Board released today the third and final part in the Alignment ...
Posted by Michael Wonder on 21 Feb 2022
Proposed PMPRB regulations requires focused dialogue with all players
16 February 2022 - Canada needs an approach that balances pricing considerations with the need to encourage investment, foster innovation, and ...
Posted by Michael Wonder on 21 Feb 2022
Drug funded for people with spinal muscular atrophy
15 February 2022 - The provincial government is covering costs for risdiplam, or Evrysdi, the medication used to treat a severe ...
Posted by Michael Wonder on 11 Feb 2022
AbbVie announces first provincial reimbursements for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients
10 February 2022 - Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance, Quebec, Saskatchewan, and ...
Posted by Michael Wonder on 09 Feb 2022
Nova Scotia becomes fifth Canadian province to implement a biosimilar switching program
5 February 2022 - The province is the latest jurisdiction to adopt a program that will require patients to switch ...
Posted by Michael Wonder on 05 Feb 2022
CADTH establishes new post-market drug evaluation program
4 February 2022 - CADTH is pleased to announce it is expanding its expertise in the management of pharmaceuticals in ...
Posted by Michael Wonder on 30 Jan 2022
Baqsimi (nasal glucagon) rescue treatment for severe hypoglycaemia now covered in Ontario
28 January 2022 - Lilly Canada is pleased to announce that as of 31 January 2022, Baqsimi (glucagon nasal powder) ...